Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.62 |
| ▸ | PPARG | P37231 | 7/20 | 0.62 |
| ▸ | PPARD | Q03181 | 7/20 | 0.62 |
| ▸ | PPARA | Q07869 | 7/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TLR2 | O60603 | 2/20 | 0.62 |
| ▸ | FABP4 | P15090 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL618898 | 0.98 | FFAR3 (0.62) | GPR84PPARGPPARDPPARAHDAC11 | |
| Butyric Acid SCHEMBL2818571 | 0.95 | FFAR3 (0.59) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octanoic Acid SCHEMBL3414554 | 0.91 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL5875269 | 0.91 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL557594 | 0.91 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heptanoate SCHEMBL3410001 | 0.91 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Undecanoate SCHEMBL21145218 | 0.91 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octanoic Acid SCHEMBL3412884 | 0.91 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL8469515 | 0.91 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL5874090 | 0.91 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2006-09-07 | — | — | US | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-0672700-A1 | PNA-synthesis using an aminoprotecting group which is labile against weak acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | GALE, GALNT2, GALNT1 | GPR84 1050/4885PPARG 2292/4885PPARD 3117/4885 |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | GPR84 2105/4885PPARG 4361/4885PPARD 4038/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | GPR84 2105/4885PPARG 4361/4885PPARD 4038/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | GPR84 1050/4885PPARG 2292/4885PPARD 3117/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | GPR84 1050/4885PPARG 2292/4885PPARD 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.